Strides aims to build on Australia and US

 
• By Aidan Fry

Unlocking the value of its “large and established portfolio in Australia and the US” by registering and marketing products in other highly regulated markets is a key facet of Strides Pharma Science’s strategy to scale up its business-to-consumer business. ‘Other Regulated Markets’ are expected to be one of the fastest-growing parts of the group.

Unlocking the value of its “large and established portfolio in Australia and the US” by registering and marketing products in other highly regulated markets is a key facet of Strides Pharma Science’s strategy to scale up its business-to-consumer business. ‘Other Regulated Markets’ are expected to be one of the fastest-growing parts of the group.

With a portfolio of more than 230 prescription and OTC molecules, Strides claims to be Australia’s third-largest generics company, covering...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business